Aardvark Therapeutics, Inc. (AARD)
| Market Cap | 165.52M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -13.85M |
| Shares Out | 21.38M |
| EPS (ttm) | -3.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 142,434 |
| Open | 8.71 |
| Previous Close | 8.90 |
| Day's Range | 7.74 - 9.16 |
| 52-Week Range | 7.74 - 19.58 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 31.50 (+306.98%) |
| Earnings Date | n/a |
About AARD
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obe... [Read more]
Analyst Forecast
According to 4 analysts, the average rating for AARD stock is "Strong Buy." The 12-month stock price forecast is $31.5, which is an increase of 306.98% from the latest price.
News
U.S. IPO Weekly Recap: Big Listings Post Mixed Results In Busy 7 IPO Week
Seven IPOs and three SPACs were listed this week. Seven IPOs and four SPACs submitted initial filings. Some small IPOs are tentatively scheduled for the short holiday week ahead.
Aardvark Therapeutics Announces Pricing of Initial Public Offering
SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (“Aardvark”) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutic...
U.S. IPO Weekly Recap: Cement And Cystic Fibrosis Drugs Lead A 6 IPO Week
Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Four small Asia-based issuers also went public in the US - EPWK Holdings, FBS Global, Plutus Financial ...
Aardvark Therapeutics Starts $100 Million IPO Effort For Hunger Treatments
Aardvark Therapeutics aims to raise $100 million in an IPO to fund its clinical-stage biopharma treatments for metabolic conditions, including Prader-Willi syndrome. Its lead candidate ARD-101, target...
Obesity biotech Aardvark eyes IPO as Ascentage makes $126M Nasdaq debut
Aardvarks pipeline is headed up by ARD-101, a bitter taste receptor pan-agonist designed to stimulate enteroendocrine cells of the digestive tract.
Aardvark Therapeutics IPO Registration Document (S-1)
Aardvark Therapeutics has filed to go public with an IPO on the NASDAQ.